Klaus Gregorius co-founded MipSalus and serves as Chief Scientific Officer. Klaus’ most prominent contributions to MipSalus are his strong innovation and scientific skills. Prior to co-founding MipSalus, Klaus worked for Danish biotech company PreciSense. Holding the position as Manager of Biochemistry Development, he spearheaded a research department focusing on receptor-ligand interactions, thus supporting the company’s development of biosensors for blood glucose monitoring for diabetics. From 1994 to 2003, Klaus held the position as Research Scientist and Project Manager at the biotech company Pharmexa developing processes and analyses for therapeutic vaccine candidates (cancer and inflammatory diseases). Klaus has published 10 peer reviewed articles and is the named inventor of 17 patent applications. His professional background also includes a position as visiting Research Fellow at Linnaeus University, Kalmar. Klaus was born in 1961 and holds a MSc in Biochemistry from the University of Copenhagen and a PhD in Chemistry from the Royal Danish Veterinary and Agricultural University (today, the Faculty of Science at the University of Copenhagen).